234 related articles for article (PubMed ID: 30626204)
21. STAT1 activation by venous malformations mutant Tie2-R849W antagonizes VEGF-A-mediated angiogenic response partly via reduced bFGF production.
Huang YH; Wu MP; Pan SC; Su WC; Chen YW; Wu LW
Angiogenesis; 2013 Jan; 16(1):207-22. PubMed ID: 23086340
[TBL] [Abstract][Full Text] [Related]
22. Ponatinib reduces viability, migration, and functionality of human endothelial cells.
Gover-Proaktor A; Granot G; Shapira S; Raz O; Pasvolsky O; Nagler A; Lev DL; Inbal A; Lubin I; Raanani P; Leader A
Leuk Lymphoma; 2017 Jun; 58(6):1455-1467. PubMed ID: 27733071
[TBL] [Abstract][Full Text] [Related]
23. Somatic TEK variant with intraarticular venous malformation and knee hemarthrosis treated with rapamycin.
Adham S; Revencu N; Mestre S; Nou-Howaldt M; Vernhet-Kovacsik H; Quéré I
Mol Genet Genomic Med; 2022 Jun; 10(6):e1931. PubMed ID: 35426265
[TBL] [Abstract][Full Text] [Related]
24. Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.
Gozgit JM; Squillace RM; Wongchenko MJ; Miller D; Wardwell S; Mohemmad Q; Narasimhan NI; Wang F; Clackson T; Rivera VM
Cancer Chemother Pharmacol; 2013 May; 71(5):1315-23. PubMed ID: 23468082
[TBL] [Abstract][Full Text] [Related]
25. Tie2-R849W mutant in venous malformations chronically activates a functional STAT1 to modulate gene expression.
Hu HT; Huang YH; Chang YA; Lee CK; Jiang MJ; Wu LW
J Invest Dermatol; 2008 Sep; 128(9):2325-33. PubMed ID: 18401423
[TBL] [Abstract][Full Text] [Related]
26. Novel multiple tyrosine kinase inhibitor ponatinib inhibits bFGF-activated signaling in neuroblastoma cells and suppresses neuroblastoma growth in vivo.
Li H; Wang Y; Chen Z; Lu J; Pan J; Yu Y; Zhao Y; Zhang H; Hu T; Liu Q; Yang J
Oncotarget; 2017 Jan; 8(4):5874-5884. PubMed ID: 27564113
[TBL] [Abstract][Full Text] [Related]
27. Mutant Tie2 causing venous malformation signals through Shc.
Morris PN; Dunmore BJ; Brindle NP
Biochem Biophys Res Commun; 2006 Jul; 346(1):335-8. PubMed ID: 16756945
[TBL] [Abstract][Full Text] [Related]
28. Variable Somatic TIE2 Mutations in Half of Sporadic Venous Malformations.
Soblet J; Limaye N; Uebelhoer M; Boon LM; Vikkula M
Mol Syndromol; 2013 Apr; 4(4):179-83. PubMed ID: 23801934
[TBL] [Abstract][Full Text] [Related]
29. Somatic activating mutations in Pik3ca cause sporadic venous malformations in mice and humans.
Castillo SD; Tzouanacou E; Zaw-Thin M; Berenjeno IM; Parker VE; Chivite I; Milà-Guasch M; Pearce W; Solomon I; Angulo-Urarte A; Figueiredo AM; Dewhurst RE; Knox RG; Clark GR; Scudamore CL; Badar A; Kalber TL; Foster J; Stuckey DJ; David AL; Phillips WA; Lythgoe MF; Wilson V; Semple RK; Sebire NJ; Kinsler VA; Graupera M; Vanhaesebroeck B
Sci Transl Med; 2016 Mar; 8(332):332ra43. PubMed ID: 27030595
[TBL] [Abstract][Full Text] [Related]
30. Somatic mutations in angiopoietin receptor gene TEK cause solitary and multiple sporadic venous malformations.
Limaye N; Wouters V; Uebelhoer M; Tuominen M; Wirkkala R; Mulliken JB; Eklund L; Boon LM; Vikkula M
Nat Genet; 2009 Jan; 41(1):118-24. PubMed ID: 19079259
[TBL] [Abstract][Full Text] [Related]
31. Ponatinib for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Narayanan V; Pollyea DA; Gutman JA; Jimeno A
Drugs Today (Barc); 2013 Apr; 49(4):261-9. PubMed ID: 23616953
[TBL] [Abstract][Full Text] [Related]
32. Isoxanthohumol modulates angiogenesis and inflammation via vascular endothelial growth factor receptor, tumor necrosis factor alpha and nuclear factor kappa B pathways.
Negrão R; Duarte D; Costa R; Soares R
Biofactors; 2013; 39(6):608-22. PubMed ID: 23904052
[TBL] [Abstract][Full Text] [Related]
33. Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation.
Zirm E; Spies-Weisshart B; Heidel F; Schnetzke U; Böhmer FD; Hochhaus A; Fischer T; Scholl S
Br J Haematol; 2012 May; 157(4):483-92. PubMed ID: 22409268
[TBL] [Abstract][Full Text] [Related]
34. Tie2 in tumor endothelial signaling and survival: implications for antiangiogenic therapy.
Tsai JH; Lee WM
Mol Cancer Res; 2009 Mar; 7(3):300-10. PubMed ID: 19276184
[TBL] [Abstract][Full Text] [Related]
35. New and Emerging Targeted Therapies for Vascular Malformations.
Van Damme A; Seront E; Dekeuleneer V; Boon LM; Vikkula M
Am J Clin Dermatol; 2020 Oct; 21(5):657-668. PubMed ID: 32557381
[TBL] [Abstract][Full Text] [Related]
36. [Rapamycin opens the era of targeted molecular therapy of venous malformations].
Seront E; Limaye N; Boon LM; Vikkula M
Med Sci (Paris); 2016; 32(6-7):574-8. PubMed ID: 27406763
[No Abstract] [Full Text] [Related]
37. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
Ewald F; Grabinski N; Grottke A; Windhorst S; Nörz D; Carstensen L; Staufer K; Hofmann BT; Diehl F; David K; Schumacher U; Nashan B; Jücker M
Int J Cancer; 2013 Nov; 133(9):2065-76. PubMed ID: 23588885
[TBL] [Abstract][Full Text] [Related]
38. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
[TBL] [Abstract][Full Text] [Related]
39. c-ABL modulates MAP kinases activation downstream of VEGFR-2 signaling by direct phosphorylation of the adaptor proteins GRB2 and NCK1.
Anselmi F; Orlandini M; Rocchigiani M; De Clemente C; Salameh A; Lentucci C; Oliviero S; Galvagni F
Angiogenesis; 2012 Jun; 15(2):187-97. PubMed ID: 22327338
[TBL] [Abstract][Full Text] [Related]
40. A Tie2 kinase mutation causing venous malformations increases phosphorylation rates and enhances cooperativity.
Kennedy MA; Xu Z; Wu Y; Sohl CD
Biochem Biophys Res Commun; 2019 Feb; 509(4):898-902. PubMed ID: 30638931
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
